KFDA approves Erivedge for basal cell carcinoma

Published: 2013-03-14 06:58:00

Updated: 2013-03-14 06:58:00

The Korea Food and Drug Administration said Tuesday that it approved Erivedge (vismodegib 150 mg) as a new treatment for adult patients with basal cell carcinoma, the most common type of skin cancer.

Developed by South San Francisco based-Genentech, a member of the Roche Group, Erivedge is int...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK